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Abstract
BACKGROUND—Diffuse low-grade and intermediate-grade gliomas (which together make up 
the lower-grade gliomas, World Health Organization grades II and III) have highly variable 
clinical behavior that is not adequately predicted on the basis of histologic class. Some are 
indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver 
variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of 
chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant 
markers of lower-grade gliomas.
METHODS—We performed genomewide analyses of 293 lower-grade gliomas from adults, 
incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA 
expression, microRNA expression, and targeted protein expression. These data were integrated 
and tested for correlation with clinical outcomes.
RESULTS—Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and 
DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, 
prognostically significant subtypes of lower-grade glioma that were captured more accurately by 
IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with 
an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas 
harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade 
gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX 
inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had 
genomic aberrations and clinical behavior strikingly similar to those found in primary 
glioblastoma.
CONCLUSIONS—The integration of genomewide data from multiple platforms delineated three 
molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 
status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q 
codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were 
molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.)
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Diffuse low-grade and intermediate-grade gliomas (World Health Organization [WHO] 
grades II and III, hereafter called lower-grade gliomas) (see the Glossary) are infiltrative 
neoplasms that arise most often in the cerebral hemispheres of adults and include 
astrocytomas, oligodendrogliomas, and oligoastrocytomas.1,2 Because of their highly 
invasive nature, complete neurosurgical resection is impossible, and the presence of residual 
tumor results in recurrence and malignant progression, albeit at highly variable intervals. A 
subset of these gliomas will progress to glioblastoma (WHO grade IV gliomas) within 
months, whereas others remain stable for years. Similarly, survival ranges widely, from 1 to 
15 years, and some lower-grade gliomas have impressive therapeutic sensitivity.3–5 Current 
treatment varies with the extent of resection, histologic class, grade, and the results of 
ancillary testing and includes clinical monitoring, chemotherapy, and radiation therapy, with 
salvage options available in the event of treatment failure.6–8
Although the histopathological classification of lower-grade gliomas is time-honored, it 
suffers from high intraobserver and interobserver variability and does not adequately predict 
clinical outcomes.9,10 Consequently, clinicians increasingly rely on genetic classification to 
guide clinical decision making.11–14 Mutations in IDH1 and IDH2 (two very similar genes, 
hereafter referred to collectively as IDH) characterize the majority of lower-grade gliomas in 
adults and define a subtype that is associated with a favorable prognosis.15–17 Lower-grade 
gliomas with both an IDH mutation (i.e., a mutation in either IDH1 or IDH2) and deletion of 
chromosome arms 1p and 19q (1p/19q codeletion), which occurs most often in 
oligodendrogliomas, have better responses to radiochemotherapy and are associated with 
longer survival than diffuse gliomas without these alterations.5,18 TP53 and ATRX mutations 
are more frequent in astrocytomas and are also important markers of clinical behavior.19 To 
gain additional insight, we performed a comprehensive, integrative analysis of 293 lower-
grade gliomas from adults, using multiple advanced molecular platforms. We performed an 
unsupervised analysis of integrated whole-genome molecular data to determine whether we 
could identify biologic classes of disease with clinically distinct behavior and to determine 
whether these classes were captured more accurately by molecular-marker status than by 
histologic class.
METHODS
PATIENTS
The tumor samples we analyzed were from 293 adults with previously untreated lower-
grade gliomas (WHO grades II and III), including 100 astrocytomas, 77 oligoastrocytomas, 
and 116 oligodendrogliomas. Pediatric lower-grade gliomas were excluded; their molecular 
pathogenesis is distinct from that of lower-grade gliomas in adults.20,21 Diagnoses were 
established at the contributing institutions; neuropathologists in our consortium reviewed the 
diagnoses and ensured the quality of the diagnoses and of the tissue for molecular profiling 
(see Supplementary Appendix 1, available with the full text of this article at NEJM.org, for 
sample inclusion criteria). Patient characteristics are described in Table 1, and in Table S1 
(Supplementary Appendix 2) and Table S2 in Supplementary Appendix 1. We obtained 
appropriate consent from relevant institutional review boards, which coordinated the consent 
process at each tissue-source site; written informed consent was obtained from all 
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participants. The patients’ ages, tumor locations, clinical histories and outcomes, tumor 
histologic classifications, and tumor grades were typical of adults with a diagnosis of diffuse 
glioma.1,2
ANALYTIC PLATFORMS
We performed exome sequencing (289 samples), DNA copy-number profiling (285), 
messenger RNA (mRNA) sequencing (277), microRNA sequencing (293), DNA 
methylation profiling (289), TERT promoter sequencing (287), and reverse-phase protein 
lysate array (RPPA) profiling (255).22 Complete data for all platforms were available for 
254 samples. Whole-genome sequencing and low-pass whole-genome sequencing were 
performed on 21 and 52 samples, respectively. Molecular data were frozen on January 31, 
2014, and clinical data were frozen on August 25, 2014. We also performed an unsupervised 
analysis (i.e., an analysis in which the categories are not known before computation) that 
integrated results from multiple platforms, including cluster of clusters (CoC) and 
OncoSign.23 In brief, CoC is a second-level clustering of class assignments derived from 
each individual molecular platform. OncoSign classifies tumors on the basis of similarities 
in recurrent mutations and copy-number variations.
The complete data sets are provided in Table S1 (Supplementary Appendix 2). The primary 
sequence files are deposited in CGHub (https://cghub.ucsc.edu); all other data, including 
mutation annotation files, are deposited at the Cancer Genome Atlas Data Coordinating 
Center (http://cancergenome.nih.gov). Sample lists, data matrixes, and supporting data are 
available at the Cancer Genome Atlas lower-grade glioma publication page (https://tcga-
data.nci.nih.gov/docs/publications/lgg_2015).
STATISTICAL ANALYSIS
The statistical analysis included Fisher’s exact test for associations of categorical variables, 
one-way analysis of variance for association with continuous outcomes, Kaplan–Meier 
estimates of survival with log-rank tests among strata, and Cox proportional-hazards 
regression for multiple-predictor models of survival. A complete description of the methods 
is provided in Supplementary Appendix 1.
RESULTS
HISTOLOGIC AND MOLECULAR SUBTYPES
To compare the results from molecular platforms with both histologic classification and 
classification based on markers frequently used in clinical practice (IDH mutation and 
1p/19q codeletion), we classified lower-grade gliomas into three categories: gliomas with an 
IDH mutation and 1p/19q codeletion, gliomas with an IDH mutation and no 1p/19q 
codeletion, and gliomas with wild-type IDH. We found a strong correlation between the 
presence of an IDH mutation and 1p/19q codeletion and the oligodendroglioma histologic 
class (69 of 84 samples) (Table 1, and Table S2 in Supplementary Appendix 1), a finding 
consistent with that in previous studies.24,25 Glioma samples with an IDH mutation and no 
1p/19q codeletion (139 samples, 50% of the cohort) represented a mixture of histologic 
classes but were enriched for astrocytomas and oligoastrocytomas. IDH wild-type samples 
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were mostly astrocytomas (31 of 55 samples) and grade III gliomas (42 of 55 samples), but 
this group included other histologic classes and grades. Overall, classification based on 
IDH–1p/19q status correlated strongly with the oligodendroglioma histologic class but only 
modestly with astrocytoma and oligoastrocytoma.
MULTIPLATFORM INTEGRATIVE ANALYSIS
To determine whether advanced molecular profiling could subdivide lower-grade gliomas 
into discrete sets that are associated with biologic characteristics of disease, we performed 
unsupervised clustering of molecular data derived from four independent platforms and 
found well-defined clusters based on DNA methylation (five clusters) (Fig. S1 through S5 in 
Supplementary Appendix 1), gene expression (four clusters) (Fig. S6 and S7 in 
Supplementary Appendix 1 and Table S7 [Supplementary Appendix 6]), DNA copy number 
(three clusters) (Fig. S8 in Supplementary Appendix 1), and microRNA expression (four 
clusters) (Fig. S9 and S10 in Supplementary Appendix 1 and Table S8 [Supplementary 
Appendix 7] and Table S9 [Supplementary Appendix 8]).22,26,27 To integrate data and 
compare the resulting biologic classes with histologic classes and subtypes based on IDH–
1p/19q status, cluster group assignments from the four individual platforms (DNA 
methylation, mRNA, DNA copy number, and microRNA) were used for a second-level CoC 
analysis, resulting in three CoC clusters with distinctive biologic themes (Fig. 1). We found 
a strong correlation between CoC cluster assignment and molecular subtypes defined on the 
basis of IDH–1p/19q codeletion status: most lower-grade gliomas with wild-type IDH were 
in the CoC cluster that included mRNA cluster R2, microRNA cluster Mi3, DNA 
methylation cluster M4, and DNA copy number cluster C2. Another CoC cluster contained 
almost all gliomas with an IDH mutation and 1p/19q codeletion and included primarily 
clusters R3, M2 and M3, and C3. The third CoC cluster was highly enriched for gliomas 
with an IDH mutation and no 1p/19q codeletion and included clusters R1, M5, C1, and Mi1.
To determine the relative strength of clinical schemes for the classification of lower-grade 
gliomas in capturing the biologic subsets revealed by CoC analysis, we compared the 
correlation between IDH–1p/19q subtype and CoC cluster assignment with the correlation 
between histologic class and CoC cluster assignment. Whereas 90% of samples with a 
specific IDH–1p/19q designation mapped one-to-one with a predominant CoC cluster, only 
63% of samples within a specific histologic class showed this predominant mapping. 
Moreover, the concordance between IDH–1p/19q status and CoC cluster assignment was 
much greater than that between histologic subtype and CoC cluster assignment (adjusted 
Rand index, 0.79 vs. 0.19) (Table S2E in Supplementary Appendix 1), which indicates that 
IDH–1p/19q status captures the biologic characteristics of lower-grade gliomas with greater 
fidelity than does histologic class.
MUTATIONAL LANDSCAPE OF LOWER-GRADE GLIOMAS
We generated a consensus mutation set with the use of three mutation-calling algorithms 
(see the Methods section in Supplementary Appendix 1); this yielded 9885 mutations 
detected in 289 samples (0.66 mutations per megabase in coding regions; median, 29 
mutations per sample [range, 0 to 597]). Samples of lower-grade gliomas with wild-type 
IDH had more mutations (median, 45) than did samples with an IDH mutation and 1p/19q 
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codeletion (median, 27; P<0.001) or those with an IDH mutation and no 1p/19q codeletion 
(median, 28; P<0.001) (Fig. S11, S12, and S13 in Supplementary Appendix 1). The 
prevalence of mutations in lower-grade gliomas, per individual sample, was lower than that 
in glioblastoma, higher than that in medulloblastoma, and intermediate in the spectrum of 
Cancer Genome Atlas–reported cancers (Fig. S11 in Supplementary Appendix 1).22,28
We identified significant differences in DNA copy-number alterations and gene mutations 
among the three molecular subtypes (Fig. 2, 3, and 4, and Fig. S8 and S14 in Supplementary 
Appendix 1, Table S3 [Supplementary Appendix 3], and Table S4 in Supplementary 
Appendix 1). We found CIC mutations in 62% and FUBP1 mutations in 29% of lower-grade 
gliomas with an IDH mutation and 1p/19q codeletion, but we did not find these mutations in 
the other molecular subtypes. Among lower-grade gliomas with an IDH mutation and 
1p/19q codeletion, we also observed mutations in the PI3 kinase pathway genes PIK3CA 
(20%) and PIK3R1 (9%)29 and in NOTCH1 (31%),29–31 as well as novel mutations in 
ZBTB20 (9%) and ARID1A (6%) (Fig. 2). In addition, among lower-grade gliomas with an 
IDH mutation and 1p/19q codeletion, 96% carried activating TERT promoter mutations, 
leading to elevated TERT expression; ATRX mutations were rare in these tumors, a finding 
consistent with the mutual exclusivity of ATRX and TERT mutations14,32 (Fig. 2 and 3). 
Focal amplification of 19p13.3 was noted (Fig. 3, and Fig. S14A in Supplementary 
Appendix 1), but few recurring whole-arm copy-number alterations other than 1p/19q 
codeletion were observed (Fig. S8B in Supplementary Appendix 1). Differences in the 
prevalence of mutations and the pattern of copy-number alterations between grade II and 
grade III lower-grade gliomas with an IDH mutation and 1p/19q codeletion were modest 
(Fig.5A, and Fig. S21 in Supplementary Appendix 1).
Overall, the data suggest that lower-grade gliomas with an IDH mutation and 1p/19q co-
deletion are biologically discrete and arise from a sequence of IDH mutation, 1p/19q 
codeletion, and TERT activation; mutation of CIC and FUBP1; and activating alterations in 
the PI3 kinase pathway.29,31,32 NOTCH1 mutations in this subset of tumors probably 
inactivate the gene, because they occur at positions similar to those of NOTCH1 inactivating 
mutations in lung, head and neck, and cervical cancers and not at activation sites34 (Fig. S15 
in Supplementary Appendix 1). The results of a PARADIGM-SHIFT35 analysis (Fig. S16 in 
Appendix 1), in which downstream targets are evaluated to assess pathway status, also 
suggested that NOTCH1 mutations result in inactivation of NOTCH1 protein function. 
Previous studies identified NOTCH1 mutations in oligodendroglioma and anaplastic 
astrocytoma; we noted them most often in lower-grade gliomas with an IDH mutation and 
1p/19q codeletion, and they were rarely identified in lower-grade gliomas with an IDH 
mutation and no 1p/19q codeletion or in those with wild-type IDH (Fig. 2).29–31
Nearly all lower-grade gliomas with an IDH mutation and no 1p/19q codeletion (94%) 
harbored TP53 mutations, which suggests that this tumor class is defined by a loss of p53 
function. Inactivating alterations of ATRX were frequent (86%) and included mutations 
(79%), deletions (3%), gene fusion (2%), or a combination of these events (2%).19 TERT 
promoter mutations were rare (4%), a finding consistent with the alternative mechanism of 
lengthening telomeres that is associated with ATRX mutations.32 We observed two novel 
significantly mutated genes in lower-grade gliomas with an IDH mutation and no 1p/19q 
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codeletion: the SWI/SNF chromatin remodeler SMARCA4 (in 6% of these gliomas), which 
was previously implicated in glioma progression,36 and the translation initiation factor 
EIF1AX (in <1%), which was previously documented in uveal melanoma37 (Fig. 2, and 
Table S4 in Supplementary Appendix 1). Some lower-grade gliomas with an IDH mutation 
and no 1p/19q codeletion had focal gains of 4q12, a locus harboring PDGFRA, which 
encodes a receptor tyrosine kinase; 12q14, encompassing CDK4, which encodes a cell-cycle 
regulator; or 8q24, a broad amplicon that includes MYC (Fig. S14A in Supplementary 
Appendix 1). These findings are consonant with those in previous studies of proneural 
glioblastoma with mutated IDH1 (with respect to MYC amplification) and with wild-type 
IDH1 (with regard to CDK4 and PDGFRA amplification).22 Histologic grade III tumors in 
this subset had greater frequencies of chromosome 9p and 19q losses and of 10p gains (Fig. 
5A), yet the mutational profiles did not differ substantially between grades (Fig. S21B in 
Supplementary Appendix 1). In the class of lower-grade gliomas with an IDH mutation, our 
multiplatform analysis suggests that there is a molecular progression that starts with initial 
IDH mutation and acquisition of the glioma CpG island methylation phenotype (G-CIMP, a 
specific pattern of widespread DNA hypermethylation) and is followed by either 1p/19q 
codeletion or TP53 mutation.19,31,38
SIGNALING NETWORKS IN LOWER-GRADE GLIOMA
To incorporate mutational landscapes into an unsupervised multiplatform classification, we 
performed OncoSign analysis23 with the use of 70 selected genetic events (mutation and 
copy number alteration) and identified four dominant subtypes (OSC1 to OSC4), which 
again largely recapitulated those defined by IDH–1p/19q status (adjusted Rand index, 0.83) 
(Fig. 3, and Table S2E in Supplementary Appendix 1). OSC1 was strongly correlated with 
lower-grade gliomas with an IDH mutation and no 1p/19q codeletion, and OSC4 contained 
exclusively lower-grade gliomas with wild-type IDH. The group with an IDH mutation and 
1p/19q codeletion included both OSC2 and OSC3 lower-grade gliomas, which differed from 
one another with regard to mutations in CIC, FUBP1, and NOTCH1 yet were not 
substantially different in terms of tumor grade or patient outcome. The concordance between 
IDH–1p/19q status and classes based on two different multiplatform approaches to genomic 
data integration (CoC and OncoSign) is striking and contrasts sharply with the much weaker 
correlation between histologic subtypes and unsupervised multiplatform classes (Table S2E 
in Supplementary Appendix 1). The finding that widely available markers (IDH and 1p/19q) 
can be used to classify lower-grade gliomas with results similar to those obtained through 
the unsupervised stratification of genomewide molecular data provides an unbiased, data-
driven rationale for using IDH and 1p/19q markers to identify lower-grade glioma disease 
classes and to incorporate them into a contemporary clinical classifier.11,14,39,40
LOWER-GRADE GLIOMAS AND GLIOBLASTOMA WITH WILD-TYPE IDH
Mutations in seven genes were strongly associated with lower-grade gliomas that had wild-
type IDH. Five of these genes have been reported to be mutated in glioblastoma: PTEN (in 
23% of lower-grade gliomas with wild-type IDH), EGFR (in 27%), NF1 (in 20%), TP53 (in 
14%), and PIK3CA (in 9%).22 We also found novel mutations in PTPN11, which encodes 
protein tyrosine phosphatase non-receptor 11 (in 7%), and in PLCG1, which encodes 
phospholipase C gamma 1 (in 5%) (Fig. 2). Similarly, copy-number alterations in tumors 
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with wild-type IDH were distinct from lower-grade gliomas with mutated IDH and instead 
resembled glioblastomas with wild-type IDH (Fig. 5A). In particular, gains of chromosome 
7 and deletions of chromosome 10 co-occurred in more than 50% of tumors of this subtype 
(chromosome 7 gains, 56%; chromosome 10 deletions, 63%), yet these alterations were 
absent in groups with mutated IDH. Recurring focal amplifications containing EGFR, 
MDM4, and CDK4 (in 38%, 13%, and 7% of tumors, respectively) and focal deletions 
targeting CDKN2A and RB1 (in 63% and 25%, respectively) were the most common 
acquired copy-number variants in lower-grade gliomas with wild-type IDH, findings similar 
to those for glioblastomas with wild-type IDH (Fig. 5B). Grade II gliomas with wild-type 
IDH were uncommon (13 cases), yet they differed from those that were grade III (Fig. S21C 
and S21D in Supplementary Appendix 1) in that they were strongly enriched within the 
discrete M1 DNA methylation cluster (Fig. 1, and Fig. S1A in Supplementary Appendix 1). 
Lower-grade gliomas in the M1 cluster that had wild-type IDH and were of grade II had a 
low prevalence of mutations and copy-number alterations, and they did not have TERT 
promoter mutations, which potentially indicates that they are distinct pathologic entities. 
TERT promoter mutations were present in 64% of all lower-grade gliomas with wild-type 
IDH; when M1 lower-grade gliomas were excluded from the analysis, TERT promoter 
mutations were present in 80% of those remaining, a prevalence similar to that in primary 
glioblastoma.32
GENOMIC REARRANGEMENTS AND FUSION TRANSCRIPTS
We investigated 20 samples with the use of high-coverage whole-genome sequencing, 50 
samples with low-coverage whole-genome sequencing, and 311 samples with whole-exome 
sequencing, for structural chromosomal variants (e.g., translocations and inversions); we 
uncovered, with high confidence, 250 chromosomal rearrangements (Table S5 
[Supplementary Appendix 4]). In addition, 19 samples had evidence of extra-chromosomal 
DNA structures known as double-minute chromosomes–breakpoint-enriched regions (DM-
BERs) (Table S5 [Supplementary Appendix 4] and Fig. S17 in Supplementary Appendix 1). 
Of these, 15 occurred in lower-grade gliomas with wild-type IDH (27% of the samples) 
(Fig. 5A), a frequency similar to that seen with glioblastoma (23%).41,42 In an analysis of 
RNA sequencing data, we identified fusion transcripts in 265 lower-grade gliomas (Table S6 
[Supplementary Appendix 5]), and correlation with structural genomic variants suggested 
chimeric transcription for 44% of the high-confidence chromosomal rearrangements, 
including two EGFR fusions (Fig. 5B), and for 58% of DM-BERs.43,44 Several genes 
(EGFR, FGFR3, NOTCH1, ATRX, and CDK4) were affected by fusions in multiple samples 
(Fig. S18A and S18B in Supplementary Appendix 1). Fusions that were predicted to activate 
EGFR and FGFR3 were restricted to lower-grade gliomas with wild-type IDH and were 
noted at frequencies similar to those in glioblastoma (7% and 3%, respectively) (Fig. S18A, 
S18B, and S19 in Supplementary Appendix 1).45,46 A novel chimeric FGFR3-ELAVL3 
transcript involved the same breakpoint as previously reported for FGFR3-TACC3 fusions 
and was highly expressed, which suggests that it could have similar effects on FGFR3 
function. Three samples had fusions between EGFR and intergenic or intronic chromosome 
7 regions that are predicted to remove the EGFR autophosphorylation domain and are likely 
to be oncogenic (Fig. S18 in Supplementary Appendix 1).47 Fusions involving genes 
encoding receptor tyrosine kinases were predominantly a feature of lower-grade gliomas 
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with wild-type IDH; only two lower-grade gliomas with an IDH mutation and no 1p/19q 
codeletion harbored such fusions (involving PDGFRA and MET), and none were identified 
among lower-grade gliomas with an IDH mutation and 1p/19q codeletion.
PROTEIN EXPRESSION
RPPA analysis resulted in protein-expression profiles that showed a striking segregation of 
lower-grade gliomas with wild-type IDH from those with mutated IDH, as well as the 
activation of receptor tyrosine kinase pathways (such as the EGFR pathway) in tumors with 
wild-type IDH, which provides additional support for the biologic similarity between lower-
grade gliomas with wild-type IDH and glioblastoma (Fig. S20 in Supplementary Appendix 
1). We observed over-expression of HER2, a potential therapeutic target, in tumors with 
wild-type IDH. Among lower-grade gliomas with mutated IDH, we observed higher 
expression of tyrosine protein kinase SYK, E-cadherin, and annexin 1 in the group without 
1p/19q codeletion. Among lower-grade gliomas with an IDH mutation and 1p/19q 
codeletion, we noted higher levels of HER3 with a phosphorylated tyrosine residue at 
position 1289, a marker that potentially confers resistance to PI3 kinase inhibitors.48
FROM SIGNATURES TO PATHWAYS
To gain insights into signaling pathways, we performed an integrated analysis of mutations, 
focal copy-number alterations, structural variants, and fusions affecting genes that encode 
receptor tyro-sine kinases (EGFR, PDGFRA, MET, and FGFR), PI3 kinase subunits, MAP 
kinases NF1 and BRAF, components of the p53 and RB1 pathways (MDM2, MDM4, 
MDM1, CDKN2A and CDKN2B [hereafter referred to as CDKN2A/B], and CDKN2C), and 
ATRX. Alterations across these loci were remarkably similar in frequency between lower-
grade gliomas with wild-type IDH and glioblastomas with wild-type IDH but not between 
these groups and other subtypes of lower-grade glioma (Fig. 5B, and Fig. S21E in 
Supplementary Appendix 1).22 A total of 43% of lower-grade gliomas with wild-type IDH 
and 53% of glioblastomas with wild-type IDH harbored EGFR alterations, with EGFR 
amplification being the most common aberration in both (Fig. S21 in Supplementary 
Appendix 1). Homozygous CDKN2A/B deletions occurred in 45% of lower-grade gliomas 
with wild-type IDH, which is similar to the frequency of these deletions in glioblastomas 
with wild-type IDH (55%). This contrasts with lower-grade gliomas with an IDH mutation 
and no 1p/19q codeletion, in which large single-copy deletions of chromosome 9p were 
common, yet CDKN2A/B was homozygously deleted in only 4% (Fig. S14B in 
Supplementary Appendix 1). Lower-grade gliomas with mutated IDH did not have cancer 
pathway aberrations similar to those of glioblastoma with wild-type IDH; instead, they had 
characteristic cancer pathway alterations in TP53 and ATRX (in the group with IDH 
mutation and no 1p/19q codeletion) and in TERT, NOTCH1, CIC, and FUBP1 (in the group 
with IDH mutation and 1p/19q codeletion) (Fig. S21E in Supplementary Appendix 1).
CLINICAL CHARACTERISTICS AND OUTCOMES ASSOCIATED WITH MOLECULAR 
SUBTYPES
Patients who had lower-grade gliomas with wild-type IDH were older than those who had 
lower-grade gliomas with mutated IDH and were more likely to have a family history of 
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cancer (Table 1, and Table S2 in Supplementary Appendix 1). The anatomical locations of 
the tumors also differed; lower-grade gliomas with mutated IDH arose in frontal lobes more 
often than did those with wild-type IDH (P<0.05). Among the patients for whom clinical 
follow-up data were available, 77 of 250 (31%) had tumor recurrence, and 60 of 289 (21%) 
were deceased at the time of analysis. Patients who had lower-grade gliomas with wild-type 
IDH had substantially shorter overall survival than did those with lower-grade gliomas with 
mutated IDH (age-adjusted hazard ratio for death, 7.4; 95% confidence interval, 4.0 to 13.8). 
Their prognosis (median survival, 1.7 years) was intermediate between those of persons who 
had glioblastomas with wild-type IDH (median survival, 1.1 years) and persons who had 
glioblastomas with mutated IDH (median survival, 2.1 years) (Fig. 6B, and Table S2D in 
Supplementary Appendix 1). In comparison, persons who had lower-grade gliomas with an 
IDH mutation and 1p/19q codeletion had a median survival of 8.0 years, and those with an 
IDH mutation and no codeletion had a median survival of 6.3 years.
The molecular classification of lower-grade gliomas as having wild-type IDH, IDH mutation 
with no 1p/19q codeletion, or IDH mutation with 1p/19q codeletion stratified patient 
outcomes in multiple-predictor models after adjustment for age and extent of resection 
(Table S2B, S2C, and S2D in Supplementary Appendix 1). Grade, but not histologic class, 
remained a significant predictor of outcome in multivariable models with IDH–1p/19q status 
and provided additional prognostic value among the molecular subsets (Table S2 and Fig. 
S22 in Supplementary Appendix 1). Together, the results point to three robust tumor classes 
in lower-grade glioma, each with prototypical molecular alterations and distinctive clinical 
behavior (Fig. 4 and 6B).
DISCUSSION
We used a comprehensive, multiplatform genomics approach to delineate the biologic 
foundations of adult lower-grade glioma and conclude that genetic status was more 
reflective of disease subtypes than was histologic class. We base this conclusion on the 
results of an unsupervised analysis of genomewide molecular platforms, in which we 
identified three cohesive tumor classes that had distinct clinical behavior and were 
concordant with IDH, 1p/19q, and TP53 status to a greater extent than with histologic class. 
The three nonoverlapping molecular subtypes distilled from the six histologic and grade 
combinations lay the foundation for a reproducible and clinically relevant classification that 
incorporates molecular data into the pathological diagnosis, as is planned for the upcoming 
revision of the WHO classification of brain tumors.39,40 More specifically, we observed that 
two unsupervised, integrative genomewide analyses independently uncovered three primary 
lower-grade glioma disease classes that were best represented by IDH and 1p/19q status; 
that lower-grade gliomas with an IDH mutation had either 1p/19q codeletion or a TP53 
mutation in a mutually exclusive fashion, which indicates a strict molecular dichotomy; and 
that the majority of lower-grade gliomas with wild-type IDH showed remarkable genomic 
and clinical similarity to primary (wild-type IDH) glioblastoma.
Numerous studies have shown that the histopathological classification of diffuse gliomas is 
prone to high interobserver variation, correlates inconsistently with genetic markers, and 
imperfectly predicts clinical outcomes.9,10 Like others, we found that lower-grade gliomas 
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with an IDH mutation and 1p/19q codeletion were of the oligodendroglioma histologic class 
and were associated with favorable outcomes.1,4,14,18,24,49 However, lower-grade gliomas 
with wild-type IDH and those with mutated IDH and no 1p/19q codeletion had substantial 
representation from all three histologic classes (astrocytoma, oligodendroglioma, and 
oligoastrocytoma), which highlights the discordance between histologic and genetic 
markers. In comparison, two unsupervised methods that integrated multiplatform molecular 
data (CoC and OncoSign) yielded strong correlations with IDH–1p/19q status (adjusted 
Rand index, 0.79 and 0.83, respectively), which showed that molecular classification 
captured biologic classes of disease more accurately than did histologic classification.
In addition, whereas oligodendrogliomas typically had 1p/19q codeletion and astrocytomas 
typically did not, oligoastrocytomas were distributed among the three molecular subtypes 
with no molecular feature distinguishing them. Thus, although previous WHO 
classifications have recognized lower-grade gliomas with mixed histologic features 
(oligoastrocytoma), our results indicate that lower-grade gliomas with an IDH mutation have 
either 1p/19q codeletion or a TP53 mutation, with few gaps or overlaps, reflecting two 
distinct molecular mechanisms of oncogenesis, and they do not provide evidence for a 
biologic or genetic signature specific to oligoastrocytoma (Fig. 2, 3, and 4); this observation 
is consistent with those in previous studies.38,49–51 Molecular signatures of lower-grade 
glioma lend themselves to a practice-altering, biologically based classification system that 
should improve interobserver concordance. The implementation of this type of system also 
seems likely to reduce the diagnosis of “oligoastrocytoma” and the confusion related to its 
clinical management.
Another substantial finding was that tumors with wild-type IDH were molecularly and 
clinically distinct from subtypes with mutated IDH, with most showing a striking 
resemblance to primary glioblastoma on all analytic platforms. These findings suggest that 
lower-grade gliomas with wild-type IDH are likely to be immediate precursors of 
glioblastoma with wild-type IDH, since the median survival associated with this type of 
lower-grade glioma was only slightly longer than that associated with this type of 
glioblastoma (Fig. 6B). Alternatively, such tumors could represent glioblastomas that were 
incompletely sampled during surgery, in which case definitive histologic classification 
would be precluded. From a practical standpoint, sampling errors represent a challenge in 
surgical neuropathology, regardless of IDH status, class, or grade, because a histologic 
diagnosis is limited to findings under the microscope. Thus, molecular classification based 
on IDH–1p/19q status represents an improvement in diagnostic practice because it enables 
the identification of a clinically aggressive form of lower-grade glioma (with wild-type 
IDH) in the absence of morphologic criteria for glioblastoma.15,17
Our analysis of clinical outcomes showed that persons who had lower-grade gliomas with an 
IDH mutation and no 1p/19q codeletion had shorter overall survival than did those who had 
lower-grade gliomas with an IDH mutation with codeletion, yet both of these groups had 
substantially longer overall survival than did persons who had lower-grade gliomas with 
wild-type IDH.15 The stratification of clinical risk on the basis of IDH–1p/19q status is more 
robust than outcome predictions based on histologic class (Fig. 6, and Table S2 and Fig. S22 
in Supplementary Appendix 1). Molecular classification can also provide quality control for 
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histopathological diagnosis. For example, tumors in the small, discrete DNA methylation 
cluster M1 had a low frequency of mutations and copy-number alterations, yet tumors in this 
group occasionally contained BRAF alterations. Although they are not entirely specific, 
these alterations are more characteristic of grade I circumscribed tumors, such as pilocytic 
astrocytoma and ganglioglioma, and their presence would prompt consideration of 
alternative diagnoses.1,13 Although diffuse gliomas and circumscribed gliomas can 
occasionally overlap histologically, their associated prognosis and clinical management 
differ greatly. Molecular signatures offer the potential to resolve these diagnostically 
challenging cases.14 Further analysis of survival data in our cohort as it matures will be 
required to improve risk stratification with the use of molecular markers. In addition, 
ongoing acquisition and maturation of detailed data on treatment and outcomes will aid in 
the delineation of markers that are predictive of therapeutic response. In the meantime, 
however, the use of molecular classification can be integrated with other clinical, 
neuroimaging, and pathological data to devise a treatment strategy for individual patients.
It may transpire that distinct therapeutic strategies are required for effective disease control 
in molecular subtypes of lower-grade glioma. Molecular inclusion criteria and stratification 
in clinical-trial design will be necessary for a clear interpretation of outcomes from specific 
treatments. The prevalence of IDH mutations in lower-grade glioma invites targeting of 
either the mutant enzymes themselves or their downstream metabolic and epigenomic 
consequences, such as G-CIMP.52 Mutations in ATRX, CIC, and FUBP1 have only recently 
been implicated in cancer pathogenesis, yet their specificity and prevalence in lower-grade 
glioma with an IDH mutation support central roles in oncogenesis and argue for thorough 
characterization of associated signaling networks to facilitate therapeutic development. The 
genetic and clinical similarities between lower-grade glioma with wild-type IDH and 
primary glioblastoma support the potential inclusion of this type of lower-grade glioma 
within the broad spectrum of glioblastoma-related clinical investigation and treatment 
protocols. Finally, our integrative analysis has shown that all subtypes of lower-grade 
glioma rely to some extent on core signaling networks that have previously been implicated 
in glioblastoma pathogenesis, many of which are targeted by agents that are being evaluated 
in clinical trials.
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Glossary
Adjusted Rand 
index
A measure of the similarity between two data clusterings, adjusted 
for chance grouping of the elements
Cluster of clusters 
(CoC) analysis
A method of obtaining clusters (e.g., of patient samples) that 
represent a consensus among the individual data types (in this 
study, we incorporated DNA methylation, DNA copy number, 
mRNA expression, and microRNA expression into the analysis)
Double-minute 
chromosome–
breakpoint-
enriched region 
(DM-BER)
As detected by whole-exome and whole-genome sequencing, 
highly amplified gene regions that are connected by DNA 
rearrangement breakpoints and allow cancer cells to maintain high 
levels of oncogene amplification
Exon The portion of a gene that encodes amino acids to form a protein
Fusion transcript A transcript composed of parts of two separate genes joined 
together by a chromosomal rearrangement, in some cases with 
functional consequences for oncogenesis, therapy, or both
Glioblastoma The highest-grade (World Health Organization grade IV) and most 
frequently occurring form of diffusely infiltrative astrocytoma. It 
arises most often in the cerebral hemispheres of adults and is 
distinguished histopathologically from diffuse lower-grade 
astrocytomas (grades II and III) by the presence of necrosis or 
microvascular proliferation
Lower-grade 
glioma
A diffusely infiltrative low-grade or intermediate-grade glioma 
(World Health Organization grade II or III) that arises most often in 
the cerebral hemispheres of adults and includes astrocytomas, 
oligodendrogliomas, and oligoastrocytomas
Methylation The attachment of methyl groups to DNA at cytosine bases. 
Methylation is correlated with reduced transcription of the gene 
immediately downstream of the methylated site
microRNA A short regulatory form of RNA that binds to a target RNA and 
generally suppresses its translation by ribosomes
Molecular subtype Subgroup of a tumor type based on molecular characteristics (rather 
than, e.g., histologic or clinical features); in this study, a molecular 
subtype is one of three classes based on IDH mutation and 1p/19q 
codeletion status
Mutation 
frequency
The number of mutations detected per megabase of DNA
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Significantly 
mutated gene
A gene with a greater number of mutations than expected on the 
basis of the background mutation rate, which suggests a role in 
oncogenesis
Whole-exome 
sequencing
Sequencing of the coding regions, or exons, of an entire genome
Whole-genome 
sequencing
Sequencing of the entire genome
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Figure 1. Cluster of Clusters (CoC) Analysis
The results of multiplatform analyses point to biologic subtypes defined by IDH mutation 
and 1p/19q codeletion status. CoC analysis uses the cluster assignments derived from 
individual molecular platforms to stratify tumors, thereby integrating data from analysis of 
messenger RNA (mRNA) (designated by R on the y axis), microRNA (mi), DNA 
methylation (M), and copy number (C). For each sample, membership in a particular cluster 
is indicated by a yellow tick, and nonmembership is indicated by a blue tick. CoC analysis 
resulted in a strong three-class solution, and a comparison of tracks for CoC consensus 
cluster with tracks for histologic and molecular class shows a stronger correlation with 
molecular class.
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Figure 2. Mutational Landscape of Somatic Alterations in Lower-Grade Glioma
At the top of the figure, somatic mutation rates for each patient are stratified according to 
nonsynonymous (blue) and synonymous (green) mutations. In the middle portion of the 
figure, the clinical features associated with the patients are shown. At the bottom of the 
figure, genes that are significantly mutated (q value <0.1, determined with the use of the 
MutSig2CV algorithm) in lower-grade glioma are listed on the right. Samples from patients 
have been separated according to IDH mutation and 1p/19q codeletion status, with mutation 
types indicated in specific colors. NA denotes not applicable.
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Figure 3. OncoSign Analysis
Four main classes (OncoSign classes [OSCs]) can be identified by means of unbiased 
clustering of tumors on the basis of recurrent copy-number alterations, mutations, and gene 
fusions. White indicates that no information was available. OSCs are largely consistent with 
the molecular subtypes identified on the basis of IDH mutation and 1p/19q codeletion status, 
and they also correlate with the results of single-platform analysis. Combinations of selected 
genomic events, termed oncogenic signatures, characterize each OSC. A small group of 
samples showed none of the recurrent events used in this analysis and were therefore 
categorized as unclassified. TERT promoter mutation and gene overexpression were found 
to be mutually exclusive with loss of ATRX and reduced gene expression, a finding 
consistent with the hypothesis that both alterations have a similar effect on telomere 
maintenance. The abbreviation miRNA denotes microRNA, and RPPA reverse-phase 
protein lysate array.
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Figure 4. Summary of Major Findings
Shown is a schematic representation that summarizes the major molecular findings and 
conclusions of our study: consensus clustering yielded three robust groups that were 
strongly correlated with IDH mutation and 1p/19q codeletion status and had stereotypical 
and subtype-specific molecular alterations and distinct clinical presentations. GBM denotes 
glioblastoma, and LGG lower-grade glioma.
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Figure 5. LGGs and GBMs with Wild-Type IDH
Panel A shows the frequency of large-scale copy-number alterations in specific molecular 
subtypes of LGG, which have been divided according to histologic grade. The University of 
California, Santa Cruz (UCSC), Cancer Genomics Browser33 (https://genome-cancer.ucsc.-
edu) was used to visualize GISTIC thresholded copy-number calls across the indicated 
chromosomes. Each vertical line indicates the copy number for an individual sample, 
colored red (amplification), blue (deletion), or white (normal), at each genomic position. 
Percentages for the indicated copy-number alteration are shown in the bar graphs on the 
right. LGGs with wild-type IDH had frequencies of gains and losses similar to those of 
GBMs with wild-type IDH (from previously published Cancer Genome Atlas data22) and 
were distinct from LGGs with mutated IDH. DM/HSR denotes double-minute chromosomes 
or homogeneously staining regions. Panel B shows the frequencies in the indicated LGG 
molecular subtypes of mutational events that are commonly found in GBM with wild-type 
IDH, including LGGs with IDH mutation and 1p/19q codeletion (85 samples), IDH 
mutation and no codeletion (141), and wild-type IDH (56). SNV denotes single-nucleotide 
variant, and SV structural variant. Differences in mutational frequency according to tumor 
grade are shown in Fig. S21 in Supplementary Appendix 1.
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Figure 6. Clinical Outcomes
Panel A shows Kaplan–Meier estimates of overall survival among patients with LGGs that 
are classified according to traditional histologic type and grade. GBM samples (from 
previously published Cancer Genome Atlas data22) are also included for comparison. Panel 
B shows overall survival among patients with LGGs that are classified according to IDH 
mutation and 1p/19q codeletion status. GBM samples classified according to IDH mutation 
status are also included. The results of an age-adjusted analysis are provided in Table S2 in 
Supplementary Appendix 1, and further division according to histologic type, grade, and 
molecular subtype is shown in Fig. S22 in Supplementary Appendix 1.
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Table 1
Clinical Characteristics of the Sample Set According to IDH Mutation and 1p/19q Codeletion Status.*
Characteristic Total (N = 278)†
IDH Mutation and 
1p/19q Codeletion (N = 
84)
IDH Mutation and No 
1p/19q Codeletion(N = 
139)
IDH Wild Type(N = 
55)
Histologic type‡ and grade‡ — no. (%)
 Oligodendroglioma
  Grade II 65 (23) 38 (45) 21 (15) 6 (11)
  Grade III 44 (16) 31 (37) 6 (4) 7 (13)
 Oligoastrocytoma
  Grade II 41 (15) 9 (11) 30 (22) 2 (4)
  Grade III 33 (12) 4 (5) 20 (14) 9 (16)
 Astrocytoma
  Grade II 30 (11) 1 (1) 24 (17) 5 (9)
  Grade III 65 (23) 1 (1) 38 (27) 26 (47)
Age at diagnosis — yr‡
 Mean 42.6±13.5 45.4±13.2 38.1±10.9 49.9±15.3
 Range 14–75 17–75 14–70 21–74
Male sex — no. (%) 155 (56) 45 (54) 84 (60) 26 (47)
White race — no./total no. (%)§ 261/274 (95) 79/81 (98) 131/138 (95) 51/55 (93)
Year of diagnosis — no. (%)
 Before 2005 38 (14) 10 (12) 18 (13) 10 (18)
 2005–2009 88 (32) 30 (36) 44 (32) 14 (25)
 2010–2013 152 (55) 44 (52) 77 (55) 31 (56)
Family history of cancer — no./total no. (%)¶
 None 108/190 (57) 30/58 (52) 64/98 (65) 13/34 (38)
 Primary brain cancer 11/190 (6) 2/58 (3) 7/98 (7) 2/34 (6)
 Other cancers 72/190 (38) 26/58 (45) 27/98 (28) 19/34 (56)
Extent of resection — no./total no. (%)
 Open biopsy 6/268 (2) 1/81 (1) 4/132 (3) 1/55 (2)
 Subtotal resection 98/268 (37) 31/81 (38) 45/132 (34) 22/55 (40)
 Gross total resection 164/268 (61) 49/81 (60) 83/132 (63) 32/55 (58)
Tumor location — no. (%)‡
 Frontal lobe 172 (62) 68 (81) 84 (60) 20 (36)
 Parietal lobe 23 (8) 5 (6) 13 (9) 5 (9)
 Temporal lobe 74 (27) 9 (11) 40 (29) 25 (45)
 Other || 9 (3) 2 (2) 2 (1) 5 (9)
Laterality — no./total no. (%)
 Left 133/276 (48) 37/84 (44) 69/137 (50) 27/55 (49)
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Characteristic Total (N = 278)†
IDH Mutation and 
1p/19q Codeletion (N = 
84)
IDH Mutation and No 
1p/19q Codeletion(N = 
139)
IDH Wild Type(N = 
55)
 Midline 5/276 (2) 2/84 (2) 2/137 (1) 1/55 (2)
 Right 138/276 (50) 45/84 (54) 66/137 (48) 27/55 (49)
White matter — no./total no. (%) 74/144 (51) 26/48 (54) 37/72 (51) 11/24 (46)
First presenting symptom — no./total no. (%)
 Headache 64/252 (25) 15/72 (21) 39/129 (30) 10/51 (20)
 Mental status change 22/252 (9) 7/72 (10) 10/129 (8) 5/51 (10)
 Motor or movement change 18/252 (7) 6/72 (8) 7/129 (5) 5/51 (10)
 Seizure 135/252 (54) 38/72 (53) 70/129 (54) 27/51 (53)
 Sensory or visual change 13/252 (5) 6/72 (8) 3/129 (2) 4/51 (8)
*
Plus–minus values are means ±SD. Categorical distributions were compared with the use of Fisher’s exact test. Analysis of variance was used to 
compare age between groups.
†
IDH–1p/19q status was not determined for 11 cases with clinical information.
‡
P<0.01 for the difference among the molecular subtypes.
§
Race was self-reported. Of the 261 patients who reported their ethnic background, 5% identified themselves as Hispanic or Latino.
¶
Included are patients for whom responses to questions regarding a family history of any cancer (192 patients) and a family history of primary 
brain cancer (197 patients) were available. P<0.05 for the difference among the molecular subtypes.
||One case (with wild-type IDH) was in the cerebellum, three cases were in the occipital lobe (two with IDH mutation and 1p/19q codeletion and 
one with an IDH mutation and no codeletion), and five cases were listed as “supratentorial, not otherwise specified” (one with an IDH mutation and 
no codeletion and four with wild-type IDH).
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